Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First-Line Treatment in Severe Hypertension
2004-000020-32Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irbesartan in hypertension (HTN) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Seated diastolic blood pressure control at Week 5. Started Jul 2005; status: completed.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2004-000020-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000020-32.